Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | DPYD | Q12882 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445690 | 0.74 | TYMP (0.56) | TYMPNPC1ATAD2LMNAGDA | |
| SCHEMBL11616197 | 0.70 | JAK2 (0.46) | TYMPNPC1ATAD2LMNAGDA | |
| SCHEMBL2891489 | 0.70 | TYMP (0.52) | TYMPNPC1SMN1; SMN2 | |
| SCHEMBL13436880 | 0.70 | TYMP (0.41) | TYMPNPC1ATAD2LMNAGDA | |
| SCHEMBL2888237 | 0.70 | TYMP (0.52) | TYMPNPC1LMNA | |
| SCHEMBL9243616 | 0.70 | TYMP (0.52) | TYMPDPYDGDAKMT2AMEN1 | |
| SCHEMBL4561126 | 0.70 | TYMP (0.52) | TYMPNPC1LMNA | |
| SCHEMBL4560955 | 0.70 | TYMP (0.52) | TYMPNPC1SMN1; SMN2 | |
| SCHEMBL13932516 | 0.70 | TYMP (0.41) | TYMPNPC1ATAD2LMNAGDA | |
| SCHEMBL2891526 | 0.70 | TYMP (0.52) | TYMPNPC1ATAD2LMNAGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053723-B | Sulfonamide derivatives and pharmaceutical use thereof | EA制药株式会社 | 2021-09-03 | — | — | CN | disclosed |
| US-10011602-B2 | Immunological reagents and uses therefor | THE UNIVERSITY OF MELBOURNE (AU) | 2018-07-03 | — | — | US | disclosed |
| US-9822110-B2 | Sulfonamide derivative and pharmaceutical use thereof | EA PHARMA CO., LTD. (JP) | 2017-11-21 | — | — | US | disclosed |
| US-20160244451-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-1237878-B1 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1237878-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6380387-B1 | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS | HOFFMANN-LA ROCHE INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2001042225-A2 | 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244451-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | ITGA1, ITGB7, ITGB4 | TYMP 3977/4885NPC1 3082/4885DPYD 1084/4885 |
| US-10011602-B2 | Immunological reagents and uses therefor | CD81, MRGPRX1, MRGPRX2 | TYMP 4406/4885NPC1 1302/4885DPYD 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.